Literature DB >> 29352659

Microwave ablation provides better survival than liver resection for hepatocellular carcinoma in patients with borderline liver function: application of ALBI score to patient selection.

Charing C N Chong1, Kit-Fai Lee1, Cheuk-Man Chu2, Anthony W H Chan3, John Wong1, Stephen L Chan4, Hon-Ting Lok1, Andrew K Y Fung1, Anthony K W Fong1, Yue S Cheung1, Simon C H Yu2, Philip Johnson5, Paul B S Lai6.   

Abstract

BACKGROUND: Studies comparing microwave ablation (MWA) and liver resection are lacking. This study evaluates the survival of patients with hepatocellular carcinoma (HCC) treated with liver resection or MWA and the role of Albumin-Bilirubin (ALBI) score in patient selection for treatments.
METHODS: This is a retrospective analysis of patients who received curative liver resection or MWA for HCC. Propensity score matching was used at a 1:1 ratio. The value of ALBI grade for patient selection was evaluated. Overall and disease-free survival were compared between two groups.
RESULTS: Of the 442 patients underwent MWA or liver resection for HCC during the study period, 63 patients received MWA and 379 patients received liver resection. Propensity scoring matching analysis resulted in 63 matched pairs for further analysis. Subgroup analysis according to the ALBI grade was performed. Liver resection offered better overall and disease-free survivals in patients with ALBI grade 1. MWA provided a significantly better overall survival (p = 0.025) and a trend towards better disease-free survival (p = 0.39) in patients with ALBI grade 2 or 3.
CONCLUSIONS: Liver resection offered superior disease-free survival to MWA in patients with HCC. The ALBI grade could identify patients with worse liver function who might gain survival advantage from MWA.
Copyright © 2018 International Hepato-Pancreato-Biliary Association Inc. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29352659     DOI: 10.1016/j.hpb.2017.12.001

Source DB:  PubMed          Journal:  HPB (Oxford)        ISSN: 1365-182X            Impact factor:   3.647


  13 in total

Review 1.  Treatment Options for Early-Stage Hepatocellular Carcinoma.

Authors:  Nora E Tabori; Gajan Sivananthan
Journal:  Semin Intervent Radiol       Date:  2020-12-11       Impact factor: 1.513

Review 2.  A review of conventional and newer generation microwave ablation systems for hepatocellular carcinoma.

Authors:  Kento Imajo; Yuji Ogawa; Masato Yoneda; Satoru Saito; Atsushi Nakajima
Journal:  J Med Ultrason (2001)       Date:  2020-01-20       Impact factor: 1.314

Review 3.  Newly Proposed ALBI Grade and ALBI-T Score as Tools for Assessment of Hepatic Function and Prognosis in Hepatocellular Carcinoma Patients.

Authors:  Atsushi Hiraoka; Takashi Kumada; Kojiro Michitaka; Masatoshi Kudo
Journal:  Liver Cancer       Date:  2018-11-29       Impact factor: 11.740

4.  Computed Tomography-Guided Percutaneous Cryoablation for ‎ Subcardiac Hepatocellular Carcinoma: Safety, Efficacy, Therapeutic Results and Risk Factors for Survival Outcomes.

Authors:  Chunhou Qi; Hongfei Gao; Qinghua Zhao; Lei Zhang
Journal:  Cancer Manag Res       Date:  2020-05-12       Impact factor: 3.989

5.  Microwave ablation compared with hepatic resection for the treatment of hepatocellular carcinoma and liver metastases: a systematic review and meta-analysis.

Authors:  Mrudula B Glassberg; Sudip Ghosh; Jeffrey W Clymer; George W J Wright; Nicole Ferko; Joseph F Amaral
Journal:  World J Surg Oncol       Date:  2019-06-10       Impact factor: 2.754

6.  Analysis of the clinical efficacy of liver resection combined with adjuvant microwave coagulation for patients with hepatocellular carcinoma.

Authors:  Ting Zhang; Mengmeng Wang; Xiangnan Zhang; Jie Hu; Weijia Dou; Qingling Fan; Dayun Feng; Lei Liu
Journal:  Ann Transl Med       Date:  2020-05

7.  Direct-acting antivirals improve survival and recurrence rates after treatment of hepatocellular carcinoma within the Milan criteria.

Authors:  Hironori Ochi; Atsushi Hiraoka; Masashi Hirooka; Yohei Koizumi; Michiko Amano; Nobuaki Azemoto; Takao Watanabe; Osamu Yoshida; Yoshio Tokumoto; Toshie Mashiba; Tomoyuki Yokota; Masanori Abe; Kojiro Michitaka; Yoichi Hiasa; Kouji Joko
Journal:  J Gastroenterol       Date:  2020-12-05       Impact factor: 7.527

8.  Effect of Severity of Liver Cirrhosis on Surgical Outcomes of Hepatocellular Carcinoma After Liver Resection and Microwave Coagulation.

Authors:  Jiang Li; Hai-Su Tao; Jian Li; Wen-Qiang Wang; Wei-Wei Sheng; Zhi-Yong Huang; Er-Lei Zhang
Journal:  Front Oncol       Date:  2021-10-06       Impact factor: 6.244

9.  Microwave ablation versus resection for hepatocellular carcinoma within the Milan criteria: a propensity-score analysis.

Authors:  Wenwu Liu; Ruhai Zou; Chenwei Wang; Jiliang Qiu; Jingxian Shen; Yadi Liao; Zhiwen Yang; Yuanping Zhang; Yongjin Wang; Yichuan Yuan; Kai Li; Dinglan Zuo; Wei He; Yun Zheng; Binkui Li; Yunfei Yuan
Journal:  Ther Adv Med Oncol       Date:  2019-09-11       Impact factor: 8.168

10.  Neutrophil to lymphocyte ratio and albumin bilirubin grade in hepatocellular carcinoma: A systematic review.

Authors:  Ayman Bannaga; Ramesh P Arasaradnam
Journal:  World J Gastroenterol       Date:  2020-09-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.